MSD’s Keytruda is poised to end a 20-year drought in new advances in NHS treatment for early-stage head and neck cancer.
Otsuka buys Transcend Therapeutics for $700M upfront
Otsuka is buying neuropsychiatric drugmaker Transcend Therapeutics in a deal worth roughly $1.2 billion, further bolstering a class of drugs that are supposed to provide

